Question · asked by 1 review

Colchicine (0.5 mg three times per day) vs placebo: Adverse effects

Population
Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination; excluding those with Behcet's disease, Reiter's syndrome, recurrent erythema multiforme, viral infection, coeliac disease, Crohn's disease, ulcerative colitis, anaemia or haematinic deficiency
Intervention
Colchicine (0.5 mg three times per day)
Comparison
placebo
Outcome
Adverse effects

What each review found

Current versions only
FindingEffectStudiesGRADE certainty
Colchicine (0.5 mg three times per day) vs Placebo
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and… · 6 months
Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) (2012) · Cochrane All outcomes
There was a greater percentage of treatment interruptions in the colchicine group due to gastrointestinal adverse effects (Fisher's exact test P=0.009). The review noted potential evidence of harm at a dose of 1.5 mg…1 study · 43 participantsGRADE not reported

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Systemic interventions for recurrent aphthous stomatitis (mouth ulcers)
2012 · Cochrane All outcomes
2012-06Not listedNot assessed

The same intervention and outcome, asked in another population or against another comparator.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.